Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25728805 | 0.89 | RAB9A (0.41) | RAB9ANPC1TP53HPGDMEN1 | |
| SCHEMBL25702565 | 0.78 | HRH3 (0.41) | RAB9ANPC1TP53HPGDMEN1 | |
| SCHEMBL24672537 | 0.76 | NPC1 (0.46) | RAB9ANPC1TP53HPGDMEN1 | |
| SCHEMBL25829623 | 0.76 | NCF1 (0.58) | RAB9ANPC1TP53HPGDMEN1 | |
| SCHEMBL4444349 | 0.73 | SMN1; SMN2 (0.56) | HPGDALDH1A1HRH3CYP2D6 | |
| SCHEMBL25701785 | 0.73 | HTT (0.44) | RAB9ANPC1TP53MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5604170 | 0.72 | SMN1; SMN2 (0.54) | HPGDALDH1A1CYP2D6 | |
| SCHEMBL19087037 | 0.70 | TLR2 (0.51) | — | |
| SCHEMBL7065867 | 0.70 | TLR2 (0.51) | — | |
| SCHEMBL23634016 | 0.70 | TLR2 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | RAB9A 4270/4885NPC1 3159/4885TP53 1474/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | RAB9A 4270/4885NPC1 3159/4885TP53 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.